Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth

2026-03-05 14:41:06 ET

The last time I spoke about Day One Biopharmaceuticals ( DAWN ), it was regarding a Seeking Alpha article entitled " Day One Biopharmaceuticals: Mersana Acquisition Ignites March Towards Unmet Need ." I noted that this company had completed its acquisition of Mersana Therapeutics so that it could add an ADC directed against B7-H4 solid tumors, known as Emi-Le [emiltatug ledadotin]. However, the goal of Day One is to specifically develop this drug to target a rare type of cancer known as adenoid cystic carcinoma [ACC]. The reason why I mentioned this is to mention that this is the first of many catalysts that are expected to be released during this year. In mid-2026, it is expected that Day One is set to release updated data from the phase 1 study for this program by mid-2026. The last time I wrote about this company, I had a "Strong Buy" rating for it, and I'm going to stick with this rating....

Read the full article on Seeking Alpha

For further details see: